USANA Health Sciences, Inc. — Form 10-Q Summary
Period: The filing covers the quarter ended April 1, 2017, compared with the quarter ended April 2, 2016. Although the request metadata identifies 2016 Q1, the filing itself is for 2017 Q1. Dollar amounts below are in millions unless stated otherwise.
Business context and results
USANA develops and manufactures nutrition and personal-care products sold internationally through independent distributors and Preferred Customers. It reported approximately 574,000 active customers and one reportable segment. International markets generated 88.2% of quarterly sales.
| Metric | Q1 2017 | Q1 2016 | Change |
|---|---|---|---|
| Net sales | $255.3 | $240.4 | +6.2% |
| Gross profit / margin | $212.7 / 83.3% | $197.5 / 82.2% | Margin +1.1 percentage points |
| Operating earnings / margin | $32.9 / 12.9% | $33.5 / 13.9% | -1.8% earnings |
| Net earnings / margin | $21.4 / 8.4% | $22.3 / 9.3% | -4.2% earnings |
| Diluted EPS | $0.86 | $0.89 | -3.4% |
| Operating cash flow | $1.9 | $13.5 | Down $11.6 |
Sales growth reflected higher volume, especially in Asia Pacific, and annual price adjustments; unfavorable exchange rates reduced sales by approximately $6.2 million. Asia Pacific sales rose 10.6% reported (13.8% excluding currency effects), led by Greater China. Americas and Europe sales fell 5.9%, including a 13.1% decline in the United States. Management attributed the lower earnings to increased China-related costs, the China investigation, higher Associate incentives, and a higher effective tax rate.
- Associate incentives were 45.3% of sales, versus 44.7% a year earlier. SG&A increased $7.4 million, reflecting technology and infrastructure investment and China-related costs.
- The effective tax rate rose to 36.0% from 32.4%. Gross margin benefited from pricing, currency effects outside China, and production efficiencies.
- Net income and operating cash flow are not interchangeable: operating cash flow was affected by working-capital movements, including a $29.2 million decrease in other liabilities.
Financial position and liquidity
At April 1, 2017, cash and cash equivalents were $176.3 million, up from $175.8 million at year-end 2016; inventory was $69.7 million. Current assets were $279.2 million and current liabilities $110.9 million, for reported net working capital of $168.3 million. Stockholders’ equity was $353.9 million. The filing reports no outstanding borrowings on its $75 million Bank of America credit line; guarantees reduced availability by $4.5 million. The facility matures in April 2021 and includes financial covenants.
Cash from investing activities was a $3.3 million use, primarily property and equipment purchases. There was no net financing cash flow in Q1 2017 and no share repurchases. Management believes cash, future operating cash flow, and credit availability should cover ordinary operating and capital needs for the foreseeable future, while noting that adverse conditions or unusual capital requirements could require additional financing. Of the cash balance, $163.4 million was held internationally. Repatriating $19.6 million of indefinitely reinvested earnings would, according to the filing, incur an estimated $3.1 million tax liability.
Outlook, risks, and unusual matters
- Management’s stated priorities include expanding in China, growing active customers, improving technology and the customer experience, and extending its Preferred Customer invitation program to other markets during 2017. Incelligence products were launched in 10 markets, with six additional launches planned during the remainder of 2017 and into 2018; China launch depended on regulatory approval. No numerical earnings or revenue guidance is provided.
- USANA was conducting a voluntary internal investigation into BabyCare’s China operations and had contacted the SEC and Department of Justice. The company said it could not predict the investigation’s duration, scope, or outcome; potential government actions could result in penalties or other relief. It also reported a first-quarter regulatory inquiry resolved with a fine paid in an Associate’s name, which the company described as not quantitatively material.
- A putative shareholder securities class action filed in February 2017 alleges nondisclosure related to China reimbursement practices and FCPA compliance. The company disputed the claims and said it would defend the action. A separate shareholder derivative case concerning 2014 equity awards remained pending, with Supreme Court oral argument scheduled for May 10, 2017.
- Disclosure controls and procedures were deemed ineffective as of quarter-end because of a previously disclosed material weakness in internal control over financial reporting related to China operations. Remediation included terminating certain BabyCare personnel and revising controls and anti-corruption procedures; management expected remediation during 2017, subject to testing and demonstrated effectiveness.
- Other disclosed risks include foreign-exchange movements, dependence on the network-marketing channel and Associates, China regulatory exposure, supplier and product risks, and compliance with credit covenants. The filing says there were no material changes in market-risk disclosures from year-end 2016.
Important facts for investors to verify
- Progress and findings from the BabyCare investigation, any SEC, DOJ, or Chinese regulatory action, and related costs or business effects.
- Whether the material weakness is remediated and disclosure controls become effective after management testing.
- Customer and sales trends in Greater China versus weakness in the United States, including the effect of the Preferred Customer conversion program.
- Whether operating cash flow recovers from the low Q1 level and how working-capital changes affect cash generation.
- Credit-line covenant compliance, actual available borrowing capacity, and the tax consequences of any cash repatriation.